Radium-223 international early access program: results from the Spanish subset.
Future Oncol
; 14(1): 41-50, 2018 Jan.
Article
in En
| MEDLINE
| ID: mdl-29232987
ABSTRACT
AIM:
To report results from the Spanish subset included in the radium-223 international early access program (iEAP). PATIENTS &METHODS:
Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles.RESULTS:
The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with ≥50% confirmed declines in prostate-specific antigen was 9%. The median overall survival was 14 months. Grade 3 or 4 treatment emergent adverse events (TEAEs) occurred in 34% of patients (serious TEAEs 28%, TEAEs leading to discontinuation 27%).CONCLUSION:
Outcomes of the Spanish subset are consistent with the iEAP. Radium-223 was generally well tolerated with no safety concerns.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Radioisotopes
/
Bone Neoplasms
/
Radium
/
Prostatic Neoplasms, Castration-Resistant
Type of study:
Clinical_trials
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Future Oncol
Year:
2018
Type:
Article
Affiliation country:
Spain